Last reviewed · How we verify
AZD0837
At a glance
| Generic name | AZD0837 |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Long-term Safety in Atrial Fibrillation Patients (PHASE2)
- Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation (PHASE2)
- Atrial Fibrillation (AF) Patients Not Taking Vitamin-K Antagonist (VKA) (PHASE2)
- Effect of Ketoconazole on Biliary Excretion of AZD0837 (PHASE1)
- AZD0837 Extended Release (ER) Japan Study (PHASE1)
- Pharmacokinetics of Extended-Release Test- and Reference Formulations of AZD0837 (PHASE1)
- Excretion of Radiolabelled AZD0837 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD0837 CI brief — competitive landscape report
- AZD0837 updates RSS · CI watch RSS
- AstraZeneca portfolio CI